SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

AimedBio and Boehringer Ingelheim Begin Phase I Study of BI 4060107

The first patient has been dosed in the Phase I study of BI 4060107, an investigational antibody-drug conjugate discovered by AimedBio and developed by Boehringer Ingelheim under a global collaboration and licensing agreement.

0009K0

Related stories